

# Clinical trials of poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer in patients without BRCA mutation

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 PARP inhibitors

Trial	Treatments	Patients	Trials design and methods
<b>niraparib vs placebo</b>			
ENGOT-OV16/NOVA non-gBRCA [NCT01847274] n=138/65 follow-up:	niraparib (300 mg) once daily versus placebo	patients with platinum-sensitive, recurrent ovarian cancer	Parallel groups double-blind

## References

### ENGOT-OV16/NOVA non-gBRCA, :

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Drum A, Tinker AV, du Bois A, Gonzalez-Martn A, Follana P, Benigno B, Rosenberg P, Gilb Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375:2154-2164 [[27717299](#)]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.